(Q24247752)

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Maxwell Finland Lecture. Random gleanings from a life with the pneumococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Prevention of Pneumococcal Infection by Immunization with Capsular Polysaccharides of Streptococcus pneumoniae: Current Status of Polyvalent Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Pneumococcal Vaccine in the Institutionalized Elderly: Design of a Nonrandomized Trial and Preliminary Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Pneumococcal vaccine efficacy in selected populations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

The Pneumococcal Vaccine After 15 Years of Use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Counterpoint to 'pneumococcal vaccine after 15 years of use'

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Inefficacy of pneumococcal vaccine in a high-risk population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal immunisation and the healthy elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Prevention of otitis media in children by pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

The pneumococcus at the gates.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Effectiveness of pneumococcal polysaccharide vaccine in older adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal vaccine in aboriginal children--a randomized controlled trial involving 60 children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021

Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000422

7 January 2021